Related Experiment Video

Updated: Aug 18, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

[Trimetazidine effects on exercise tolerance and left ventricular diastolic function in patients with coronary heart

A D Kuimov, S D Maianskaia, E B Luksha

    Terapevticheskii Arkhiv
    |March 31, 1999
    PubMed

    Insights

    Trimetasidine improves exercise tolerance and left ventricular diastolic function in coronary heart disease patients. This medication enhances treatment efficacy when added to standard therapies.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Coronary heart disease (CHD) significantly impacts cardiac function and exercise capacity.
    • Left ventricular diastolic dysfunction (LVDF) is a common complication in CHD patients.
    • Standard treatments include nitrates, beta-blockers (BB), and ACE inhibitors.

    Purpose of the Study:

    • To evaluate the effects of trimetazidine on exercise tolerance (ET) and LVDF in patients with CHD.
    • To assess trimetazidine as an adjuvant therapy to standard CHD treatments.

    Main Methods:

    • A study group of 40 CHD patients received standard therapy plus trimetazidine (60 mg/d) for 2-3 months.
    • A control group of 38 CHD patients received standard therapy only.
    • Exercise tolerance was assessed using cycle ergometry.
    • Left ventricular diastolic function was evaluated using echocardiography, including stress tests.

    Main Results:

    • Trimetazidine significantly improved exercise tolerance and mean threshold capacity.
    • Adjuvant trimetazidine enhanced left ventricular diastolic function.
    • Trimetazidine mitigated LVDF impairment during dipyridamole testing when combined with beta-blockers.

    Conclusions:

    • Adding trimetazidine to combined therapy for CHD improves exercise tolerance.
    • Trimetazidine is effective in enhancing left ventricular diastolic function in CHD patients.
    • Trimetazidine offers a beneficial addition to established CHD treatment regimens.
    Abstract

    More Related Videos

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

    Published on: July 21, 2023

    Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease08:57

    Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease

    Published on: May 22, 2026

    Related Concept Videos

    Antihypertensive Drugs: Thiazide-Class Diuretics01:15

    Antihypertensive Drugs: Thiazide-Class Diuretics

    Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...